Watch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation ...
Management anticipates key 2026 catalysts: interim CBeyond extension data and FDA Type C meeting minutes in Q1, Cohort 2 enrollment initiation and completion in Q2, and top-line clinical data from the ...
Becton, Dickinson and Company ( BDX) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:30 AM EDT Good morning. Thanks very much for joining us. Very pleased today to have with us Tom ...
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...
Intraocular inflammation following high dose aflibercept may be more common in practice than phase 3 trials found.
CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority ...
A Main Line Today editor shares what happened when she had a seat and took the leap into IV therapy not once, but twice.
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, United States College of Health Solutions, Arizona State University, Phoenix, United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results